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Mature T lymphocytes are the target of choice in certain gene therapeutic strategies. [1] [2] [3] [4] To obtain stable gene expression retroviral vectors are most frequently used for gene transfer. However, using standard supernatant infections with amphotropic vectors only low transduction efficiencies have been achieved. 1, 2, 5, 6 In a bid to overcome this problem, different pseudotypes 7, 8 and infection protocols [5] [6] [7] [8] [9] [10] for human T cells have been proposed. However, several shortcomings may hinder the clinical application of these protocols. First, most recently published infection protocols used either low cell densities (Ͻ2 × 10 5 cells/ml) 5 or multiple infections 10 in order to obtain high transduction rates. Second, to our knowledge, all protocols for human primary T cells published so far are based on the use of media supplemented with foetal bovine serum (FBS), a potent immunogen 11 and possible source of biological contamination. Third, most of the protocols include complex procedures. Taken together, these limitations would impede the adaptation of existing protocols to the transduction of large numbers of T lymphocytes as needed in gene therapeutic protocols and the requirements of 'good manufacturing practice' (GMP).
We have developed an easy protocol for the efficient transduction of human primary T cells with retroviral vectors, for clinical application, using serum-free medium (SFM) for the generation of vector-containing supernatant, and SFM complemented with autologous serum during infection. Cells were infected at high densities (1 × 10 6 /ml) with retroviral vectors encoding as a gene transfer marker a truncated human low-affinity nerve growth factor receptor (⌬LNGFR) lacking the intracytoplasmatic domain. 6, 12 The use of surface proteins as gene transfer markers allows rapid and convenient determination of gene transfer efficiencies by flow cytometry. 13 The vectors were produced by a PG13 producer cell line, 14 which utilises the Gibbon ape leukaemia virus (GALV) env protein.
In an attempt to improve vector titres, we compared supernatant generation at two different temperatures (37°C and 32°C) over various incubation periods using serum-free (RPMI 1640, X-vivo 10) as well as FBS-containing media (DMEM, RPMI 1640). Obtained supernatant was used to infect CD4 + Jurkat cells in a single centrifugation-based infection cycle. 6 Three days later gene transfer was determined by flow cytometry. 6 After relatively short incubation periods (3-9 h) titres were higher at 37°C (compared with 32°C) for all media (Table 1 ). In contrast, after overnight incubation titres were higher at 32°C in FBS-containing media, but at 37°C in SFM (data not shown). Our results obtained with FBScontaining media are consistent with previously published data reporting a higher rate of virus production at 37°C coupled with decreased virus particle stability, 
Mean ± s.d. 69 ± 14 41 ± 16 60 ± 13 46 ± 14 PG13 cells releasing a retroviral vector encoding ⌬LNGFR were seeded and grown as described (see Figure 1 ). To obtain supernatant, producer cells were incubated in parallel with the respective media X-vivo 10 and DMEM + 10% FBS at both 37°C and 32°C. Supernatants were harvested after 6 h, and 1.5 ml were added to 3 × 10 6 CD4 + Jurkat cells resuspended in 1.5 ml X-vivo 10. Infection was carried out using a centrifugation step (see Figure 1 ). Transduction efficiency was measured by flow cytometry after 3 days. 6 The Wilcoxon test for comparison of two groups revealed that all differences were significant (P Ͻ 0.02) with the exception of columns 2 versus 4. Data were analysed using WinStat 3.0 (Kalmia, Cambridge, MA, USA).
which becomes more significant the longer the incubation period. 15 Considering our data using SFM, this decreased virus particle stability may at least in part be due to some temperature-dependent influence of serum. Overall, the highest titres were observed after 6 h ( Figure 1 ) incubation at 37°C in serum-free X-vivo 10 medium (approximately 5 × 10 6 infectious units (IU)/ml as determined by flow cytometry analysis;
6 Table 1 ). Retroviral vectors based on the Moloney murine leukaemia virus can only infect dividing cells. 16 Consequently, we used different protocols for the stimulation of primary T cells. After Ficoll gradient centrifugation, 6 mononuclear cells (MNC) were incubated in various cultivation media supplemented with 100 U/ml interleukin-2 (IL-2). For T cell activation we used either OKT-3 alone (in solution or immobilised) or in combination with anti-CD28 antibodies. We determined the start of cell division by flow cytometry using PKH-26, a fluorescence dye incorporated into the cell membrane. Almost all T cells entered the cell cycle on day 3 after stimulation with OKT-3 (data not shown). This corresponded well with our cell counting data demonstrating increasing T cell numbers after day 3 (see below). Activation was also measured based on the expression of cell surface markers. Although cells activated with the OKT3/anti-CD28 combination showed a remarkably higher expression of both CD25 and CD69 as determined by flow cytometry, gene transfer into T cells activated with OKT-3 alone was just as efficient. Slightly higher gene transfer was observed in cells activated using immobilised antibodies (data not shown).
During activation with OKT-3 and IL-2 (see above), cells were kept in various media: X-vivo 10, X-vivo 10 + Peripheral blood mononuclear cells (see Figure 2) were stimulated with OKT-3 and IL-2 in parallel experiments in either Xvivo 10 or RPMI 1640 in the presence versus absence of 8% heatinactivated autologous serum (AS) or 10% foetal bovine serum (FBS). Three days after initial stimulation cells were infected with X-vivo 10-based supernatant using the centrifugation protocol described (Figure 2 ). Infection was repeated after 24 h. Transduction efficiency was measured by flow cytometry after 3 days. 6 According to the Wilcoxon test the differences between columns 1-2, 1-4, 2-3 and 3-4 are significant (P Ͻ 0.05). In summary, the presence of autologous serum in the activation medium greatly enhanced gene transfer. X-vivo 10 (+AS) facilitated the highest transduction efficiency with a remarkable reproducibility. Even higher gene transfer could be achieved in later experiments, when AS was added also during the infection steps (not shown). Data were analysed using WinStat 3.0.
8% autologous serum (AS), RPMI 1640 + 10% FBS, RPMI 1640 + 8% AS. After 3 days, 3 × 10 6 of the activated T cells were resuspended in 3 ml X-vivo 10-based supernatant (see above) and centrifuged for 60 min at 1000 g and 20°C in the presence of protamine sulphate (4 g/ml) and IL-2 (100 U/ml) before overnight incubation at 37°C. In some experiments, additional stimulation with OKT-3 during the infection step was carried out. It was, however, of insignificant advantage (data not shown). Although efficient gene transfer was possible in the completely serum-free medium (X-vivo 10), additional autologous serum (8%) led to a remarkable increase of transduction efficiencies and more consistent results (Table 2) for both X-vivo 10 and RPMI 1640.
Based on these data, we then compared two different transduction protocols either using the centrifugation protocol or fibronectin (CH-296)-coated tissue culture flasks. 6 Fibronectin, a cell matrix component, enhances gene transfer by retroviral vectors into different cell types probably due to co-localisation of retroviral particles and target cells on specific fragments of the molecule. 17 We found up to 61% gene transfer using the centrifugation procedure and up to 79% on fibronectin (Table 2, Figure  2 ). This is consistent with our previous data showing a slight (about 25%) but significant increase of gene transfer into lymphocytes on FN. 6 Similar data were described in a parallel publication, 5 where up to 90% of T cells were transduced on FN, although at comparatively low cell densities (Ͻ2 × 10 5 /ml) and after triple infection. In our last step, we adapted the centrifugation-based protocol to large-scale conditions. We infected 1 × 10 8 (1/1, 1/2, 1/4 ) using centrifugation at 1000 g in the presence of protamine sulphate (4 g/ml). Gene transfer was determined 3 days after infection using anti-NGF antibodies (Boehringer Mannheim, Mannheim, Germany) and subsequent flow cytometry on a FACScan (Becton Dickinson, San Jose, CA, USA) as described. 6 
Figure 1 Determination of the optimal incubation period for the generation of retrovirus-containing supernatant by infection of CD4

Representative results of infection with 1:4 diluted supernatant from one such experiment are presented here (a-c). Most efficient transduction has been obtained using supernatant generated for 6 h at 37°C (c). Ͻ1% of the cells were positive with the respective isotype antibody (not shown).
Figure 2 Highly efficient gene transfer into primary human T cells using both a fibronectin (FN) (Retronectin; Takara, Otsu, Japan) (b, e) and a centrifugation-based (c, f) infection protocol. After Ficoll gradient centrifugation, 2 × 10
6 /ml MNC were activated with 10 ng/ml OKT-3 (Cilag, Neuss, Germany) and 100 U/ml IL-2 (PAN, Nü rnberg, Germany) for 3 days. 6 For infection, 3 × 10 6 cells were incubated in 3 ml supernatant (titre about 5 × 10 6 IU/ml) generated for 6 h at 37°C with X-vivo 10 (see Figure 1) . cells at a density of 1 × 10 6 cells/ml (ie 2 × 100 ml supernatant). As shown for two different donors in Figure 3 , after 6 days in culture we obtained more than 6 × 10 8 T cells, of which more than 60%, ie more than 3.5 × 10 8 , were genetically modified. This shows that the protocol described here enables the transduction of large cell numbers as required for clinical applications.
In summary, we have developed a protocol for the Figure 3 High gene transfer rates under large-scale conditions. After Ficoll gradient centrifugation MNC were stimulated as described above (see Figure  2 ). After 3 days 2.5 × 10 7 cells were transferred to 75 cm 2 cell culture flasks and infected with 25 ml supernatant of a PG13 cell line producing the vector SF1⌬. 19 The supernatant had been generated in X-vivo 10, filtered and stored at −80°C until use. Double infection was carried out according to the centrifugation protocol outlined above (see Figure 2) . Expression of the transgene was analysed 2 days after the last infection by flow cytometry (see Figure 2) . Panel (b) highly efficient transduction of human primary T cells, which meets the requirements for clinical application. The protocol is, to our knowledge, the first one which avoids the use of FBS-containing media during T cell transduction. The easy handling procedures make it highly compatible with the standards of GMP, while allowing the transduction of target cells at comparatively high cell densities (1 × 10 6 /ml).
Additional autologous serum both during stimulation and infection steps strongly enhanced gene transfer. Probably, this is due to some positive influence of AS on target cells (eg increased cell cycling, increased expression of Glvr-1, 18 the receptor for the retroviral particles). However, an influence on viral particles or virus-cell interaction could not be excluded. The mechanism of this effect is still under investigation.
The use of the centrifugation protocol for clinical purposes may be favoured by cost and handling factors. The fibronectin-based protocol, however, allows higher gene transfer and may be of advantage, when nearly pure populations of gene-modified cells are required without selection. According to a previously published work 5 and our own data (unpublished), more than 90% of the cells may be transduced after triple infection on fibronectin.
In conclusion, we suggest that based on our data optimal protocols can be designed for both clinical and research purposes.
